ABBOTINDIA25,230.00

Abbott India Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersPFIZERGLAXOIPCALABAJANTPHARMANTHEMMEDANTAGLENMARKBIOCON
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Revenue from Operations5,848.96,409.26,929.1
Other Income248.3275.6288.1
Total Income6,097.26,684.77,217.2
Expenses
+ Cost of Materials Consumed565.7621.1613.9
+ Purchases of Stock-in-Trade2,647.23,056.33,164.2
+ Changes in Inventories-85.3
+ Employee Benefit Expense576.6587.5668.8
+ Finance Costs12.511.425.0
+ Depreciation & Amortisation71.271.876.0
+ Other Expenses598.6675.3
Total Expenses4,479.44,797.85,137.9
EBITDA1,453.11,694.61,892.1
EBIT1,381.91,622.81,816.1
Profit
Pretax Income1,617.81,887.02,079.3
+ Current Tax39.224.7544.7
+ Deferred Tax-10.7
Tax Expense416.5472.5527.3
Net Income1,201.21,414.41,552.0
+ Other Comprehensive Income0.0-5.4-0.9
Total Comprehensive Income1,201.21,409.01,551.2
Per Share
Basic EPS565.280.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit2,636.02,731.73,236.2
Gross Margin %45.0742.6246.71
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.